Phase II Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 18 Jun 2018
At a glance
- Drugs Eribulin (Primary) ; Trastuzumab
- Indications Breast cancer
- Focus Therapeutic Use
- 07 May 2018 Status changed from active, no longer recruiting to completed.
- 08 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Jul 2018.
- 11 Apr 2017 Planned End Date changed from 1 Aug 2017 to 1 Oct 2017.